<DOC>
	<DOCNO>NCT01089881</DOCNO>
	<brief_summary>Choline one component phosphatidylcholine , essential element phospholipid cell membrane . Some malignant cell show ability actively incorporate choline produce phosphocholine phosphatidylcholine facilitate tumor cell duplication . The efficacy 18F-fluorocholine ( 18F-FCH ) localize primary metastatic prostate cancer recently report limited study . This study conduct delineate effectiveness 18F-FCH PET ( 1 ) differentiate benign prostate hypertrophy ( BPH ) prostate cancer , ( 2 ) stag prostate cancer , ( 3 ) following-up patient prostate cancer initial curative therapy .</brief_summary>
	<brief_title>The Effectiveness 18F-fluorocholine Positron Emission Tomography ( PET ) Detecting , Staging Following-up Prostate Cancer</brief_title>
	<detailed_description>Background : Prostate cancer lead cause cancer death male Taiwan . Although 18F-FDG PET show effective tool diagnose many malignancy , previous study show 18F-FDG suitable PET tracer detect prostate cancer . Choline one component phosphatidylcholine , essential element phospholipid cell membrane . Some malignant cell show ability actively incorporate choline produce phosphocholine phosphatidylcholine facilitate tumor cell duplication . The efficacy 18F-fluorocholine ( 18F-FCH ) localize primary metastatic prostate cancer recently report limited study . Purpose : This study conduct delineate effectiveness 18F-FCH PET ( 1 ) differentiate benign prostate hypertrophy ( BPH ) prostate cancer , ( 2 ) stag prostate cancer , ( 3 ) following-up patient prostate cancer initial curative therapy . Patients Methods : This study include 1 . Group 1 : 50 patient BPH 2 . Group 2 : 50 patient newly diagnose prostate cancer 3 . Group 3 : 50 patient receive curative treatment prostate cancer suspicious recurrence/metastases persistent increase serum PSA . 18F-FCH whole-body PET perform patient Expected Results : To evaluate effectiveness 18F-FCH diagnosis , stag follow-up prostate cancer .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Group 1 : 50 patient BPH 1 . Age 35 year old 2 . Histologically confirm BPH 3 . Informed consent sign Group 2 : 50 patient newly diagnose prostate cancer 1 . Age 35 year old 2 . Histologically confirm prostate cancer 3 . Informed consent sign Group 3 : 50 patient 1 . Age 35 year old 2 . Histologically confirm prostate cancer receive curative treatment prostate cancer 3. suspicious recurrence/metastases persistent increase serum PSA 4 . Informed consent sign Patients know malignancy exclude .</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>18F-fluorocholine</keyword>
	<keyword>PET</keyword>
	<keyword>recurrence</keyword>
	<keyword>metastasis</keyword>
</DOC>